# Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication

> **NCT04907747** · PHASE4 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 234 (estimated)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Vonoprazan
- **DRUG:** Esomeprazole
- **DRUG:** Colloidal bismuth pectin
- **DRUG:** Amoxicillin
- **DRUG:** Furazolidone

## Key facts

- **NCT ID:** NCT04907747
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-18
- **Primary completion:** 2022-04-13
- **Final completion:** 2022-04-13
- **Target enrollment:** 234 (ESTIMATED)
- **Last updated:** 2021-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04907747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04907747, "Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04907747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*